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Purpose: Identifying genetic risk factors for developing sarcoidosis-associated uveitis could provide in-
sights into its pathogenesis which is poorly understood.
We determine if variants in NOD2 confer an increased risk of developing uveitis in adults with
sarcoidosis.
Methods: In this genetic case-control study, 51 total subjects were enrolled: 39 patients diagnosed with
sarcoid-related uveitis and 12 patients with systemic sarcoidosis without ocular involvement as controls.
Sanger sequencing of the eleven exons of the NOD2 gene was performed on DNA obtained from whole
blood. Sanger sequencing data were aligned against the NOD2 NCBI-RefSeq reference sequence to
identify novel mutations in uveitis patients. For common variants, allele frequencies in cases versus
controls were compared using the chi-square test.
Results: There were no signiﬁcant differences in NOD2 common variant allele frequencies between
sarcoidosis patients with and without uveitis, and none of the pathogenic NOD2 mutations associated
with Blau syndrome were found in this cohort. However, four rare, non-synonymous variants were
identiﬁed in four patients with ocular sarcoidosis and none of the controls. Variants rs149071116,
rs35285618, and 16:g.50745164T > C have never been previously reported to be associated with any
disease and may be pathogenic. The fourth variant, rs2066845, is associated with Crohn’s disease and
psoriatic arthritis.
Conclusions: Despite the phenotypic overlap between sarcoidosis and Blau syndrome, none of the
established pathogenic NOD2 variants were present in adults with sarcoidosis. However, four novel, rare,
non-synonymous variants were identiﬁed in four cases with ocular sarcoidosis. Further investigation is
needed to explore the potential clinical signiﬁcance of these polymorphisms.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
NOD2 mutations have been shown to be responsible for three
granulomatous inﬂammatory diseases: Crohn’s disease, NOD2-
associated autoinﬂammatory disease and Blau syndrome [1]. Blau
syndrome is a systemic Mendelian disease whose diagnostic triad
includes uveitis, granulomatous dermatitis, and arthritis [1], and itshere previously and is not
ation.
Inﬁrmary, 243 Charles Street,
. Sobrin).
Inc. This is an open access article uphenotype overlaps signiﬁcantly with early-onset sarcoidosis.
Because of the similarity between sarcoidosis and Blau syndrome,
there is a strong rationale to investigate NOD2 variation in patients
with adult-onset sarcoidosis, particularly those who develop uveitis
as this is a characteristic of both disorders. One previous study
examined NOD2 variants in 13 patients with sarcoidosis-associated
uveitis [2]. The investigators did not ﬁnd any of the disease-causing
variants associated with Blau syndrome in sarcoidosis patients. The
purpose of this study is to investigate NOD2 variants, including those
that have been newly discovered since the previous publication, in a
larger sample size of sarcoidosis patients with andwithout uveitis to
determine if there are previously reported mutations or novel mu-
tations in NOD2 that predispose to ocular involvement.nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Patients with sarcoidosis were identiﬁed from the Ocular
Immunology and Uveitis Clinics of the Massachusetts Eye and Ear
Inﬁrmary (MEEI). This study was approved by the MEEI Institu-
tional Review Board/Human Studies Committee. Controls were
deﬁned as patients with systemic sarcoidosis but no ocular
involvement. Cases were deﬁned as having sarcoidosis-related
uveitis. Systemic sarcoidosis was deﬁned based on deﬁnitive or
presumed sarcoidosis by American Thoracic Society (ATS) and the
World Association for Sarcoidosis and Other Granulomatous Dis-
orders (WASOG) statement criteria [3]. With this criteria, diagnosis
is established by either: 1) histological conﬁrmation with evidence
of disease involvement in either the thorax or two more other or-
gan systems; or 2) characteristic chest radiographs (bilateral hilar
lymphadenopathy) plus erythema nodosum or without diagnosis
of another explanatory condition after a minimum of 2 years follow
up. Presence or absence of uveitis was determined by clinical ex-
amination by a fellowship-trained uveitis specialist. Classiﬁcation
of ophthalmic involvement was based on the criteria set forth by
the International Workshop on Ocular Sarcoidosis (IWOS) [4]. A
diagnosis of deﬁnitive ocular sarcoidosis was made in the presence
of a compatible uveitis with a conﬁrmatory biopsy. Presumed
ocular sarcoidosis was deﬁned by a compatible uveitis supported
by bilateral hilar lymphadenopathy seen on chest imaging without
a biopsy.
Sanger sequencing of the eleven exons of the NOD2 gene were
performed on DNA extracted from the participants’ blood. Sanger
sequencing data were aligned against the NOD2 NCBI-RefSeq
reference sequence. DNASTAR SeqMan Pro software was used for
quality control ﬁltering, variant calling and analysis. The variants
detected in our patients were cross-referenced against NOD2 var-
iants that have been previously associated with Blau syndrome,
sarcoidosis or Crohn’s disease [1]. They were also annotated to
identify novel rare, non-synonymous mutations in NOD2 for po-
tential functional signiﬁcance using Human BP Codon Resource
(HBCR). HBCR uses predicted sequence changes based on Ensembl
gene models, and pathogenicity data extracted from a curated
database, PolyPhen, Sorting Intolerant From Tolerant (SIFT), the
database of Non-Synonymous Functional Prediction (dbNSFP)
resource, and Combined Annotation Dependent Depletion (CADD)
scores. HBCR also annotates variants with allele frequencies in
multiple reference populations.
Baseline demographic and clinical characteristics between cases
and controls were compared using the t-test for continuous vari-
ables and the chi-square test for categorical variables. For common
NOD2 variants, allele frequencies between cases and control were
compared using the chi-square test. All statistical analyses were
performed in Stata 12.1 (College Station, Texas).Table 1
Demographic and clinical characteristics of sarcoidosis patients.
Sarcoidosis with uv
Age in years, mean (SD) 56.6 (15.1)
Gender M 11
F 28
Duration of sarcoidosis in years, mean (SD) 9.1 (7.5)
Ethnicity CA 28
AA 10
HA 1
SD ¼ standard deviation, M ¼ male, F ¼ female, CA ¼ Caucasian American, AA ¼ African
a Continuous variables compared with the t-test and categorical variables compared w3. Results
51 subjects were enrolled, including 39 patients diagnosed with
sarcoid-related uveitis as cases and 12 patients with systemic
sarcoidosis without ocular involvement as controls. Table 1 sum-
marizes the clinical characteristics of the patients. The gender, age,
race and duration of sarcoidosis were not statistically different
between cases and controls (p > 0.05).
In our patients with adult-onset sarcoidosis, we did not iden-
tify any of the single amino acid mutations in NOD2 that have been
associated with Blau syndrome [1,5]. Table 2 shows all of the
polymorphisms in NOD2 identiﬁed by sequencing in our patients.
In comparing with the previous publication on NOD2 variants in
ocular sarcoidosis, there were six variants that led to protein
changes that overlapped between the two studies. Four of them
were common variants (rs2067085, rs2066842, rs2066843,
rs1861759) and we did not ﬁnd that they were associated with
uveitis to a statistically signiﬁcant degree. The ﬁfth was a rare
variant associated with Crohn’s disease (rs2066844, MAF ¼ 0.03).
In our cohort, none of the patients with this variant had a history
of Crohn’s disease. The sixth (rs5743291) was a rare variant
associated with early onset sarcoidosis, but the frequency of this
allele was not signiﬁcantly different between those with and
without uveitis [minor allele frequencies (MAFs) ¼ 0.067 and
0.068 respectively].
We identiﬁed four rare, non-synonymous variants that were
present in only one case each. Two, rs149071116 and novel variant
NM_022162.1:c.1342T > C (NOD2:p.Ser448Pro), have never been
previously associated with any disease. SIFT, a sequence homology-
based tool that sorts intolerant from tolerant amino acid sub-
stitutions and predicts whether an amino acid substitution will
have a phenotypic effect, predicted both variants to be damaging.
Polymorphism rs149071116 was identiﬁed in a 34-year-old Asian
man with anterior uveitis in the right eye and panuveitis and
macular edema in the left eye. The patient with variant
NM_022162.1:c.1342T > C (NOD2::p.Ser448Pro) was a 36-year-old
Caucasian man with panuveitis, choroiditis, periphlebitis and
papillitis. He requiredmethotrexate in addition to his prednisone to
control his ocular inﬂammation and also had renal and pulmonary
involvement during course of his disease. The third polymorphism,
rs35285618, is a low frequency single nucleotide protein (SNP)
(MAF ¼ 0.013) located six amino acids downstream of the R702W
variant that is associated with Crohn’s disease in African Americans
[6]. It was predicted to be “possibly damaging” by PolyPhen but
“tolerated” by SIFT. It was found in a 40-year old Hispanic man of
European descent with bilateral panuveitis, lung, skin, and parotid
gland involvement. The fourth polymorphism, rs2066845, is also a
low frequency SNP that is associated with Crohn’s disease and
psoriatic arthritis [7e9]. The patient with this variant was a 64-year-eitis (n ¼ 39) Sarcoidosis without uveitis (n ¼ 12) P valuea
54.2 (6.8) 0.58
5 0.48
7
8.3 (10.3) 0.72
10 0.27
1
1
American, HA ¼ Hispanic American.
ith the chi-square test.
Table 2
NOD2 variants identiﬁed in sarcoidosis patients.
NOD2 polymorphisms identiﬁed in patients with sarcoidosis Variant allele frequency
Variants in genomic
HGVS format with
chromosome: Position
SNP rs ID number Mutation type Nucleotide change Peptide change Prior associations
with disease
Minor allele frequency from
1000 genomes
Sarcoidosis with
uveitis N ¼ 39
(allele frequency)
Sarcoidosis without
uveits N ¼ 12
(allele frequency)
P Value
Common variants (minor allele frequency  0.05)
16:g.50731096 G > A rs2076752 50 UTR 47G > A NM_022162.1:c.-59G >
A by VEP
V16 None A ¼ 0.14 19 (0.24) 6 (0.18) 0.59
16:g.50733374 G > T rs2076753 Intronic 74-25G > T NA None T ¼ 0.11 16 (0.20) 5 (0.18) 0.53
16:g.50733859 C > G rs2067085 Syn 534C > G S178S Crohn’s disease [10] G ¼ 0.24 26 (0.33) 6 (0.18) 0.20
16:g.50744624 C > T rs2066842 Non-syn 802C > T P268S None T ¼ 0.10 13 (0.17) 4 (0.13) 0.50
16:g.50745199 C > T rs2066843 Syn 1377C > T R459R Crohn’s disease [11,12] T ¼ 0.1076 15 (0.19) 5 (0.18) 0.60
16:g.50745583 T > G rs1861759 Syn 1761T > G R587R None G ¼ 0.2161 28 (0.36) 7 (0.22) 0.27
16:g.50759547 A > T rs1077861 Intron 2966 þ 64A > T NA Chronic obstructive
pulmonary disease [13]
T ¼ 0.33 39 (0.5) 11 (0.46) 0.47
Rare variants (minor allele frequency < 0.05)
16:g.50733808 C > T NA Syn 483C > T F161F None T ¼ 0.0026 1 (0.01) 0 (0) NA
16:g.50741800a C > T rs149071116 Non-syn 575C > T A192V None NA 1 (0.01) 0 (0) NA
16:g.50744638 C > T rs35090774 Syn 816C > T S272S None T ¼ 0.0042 1 (0.01) 0 (0) NA
16:g.50745164a T > C NA Non-syn 1342T > C S448P None NA 1 (0.01) 0 (0) NA
16:g.50745275 C > T rs5743274 Syn 1453C > T L485L None T ¼ 0.01 1 (0.01) 0 (0) NA
16:g.50745655 C > T rs61736932 Syn 1833C > T A611A Crohn’s disease,
Ulcerative colitis [14]
T ¼ 0.0026 1 (0.01) 0 (0) NA
16:g.50745926 C > T rs2066844 Non-syn 2104C > T R702W Crohn’s disease [7] T ¼ 0.01 2 (0.02) 1 (0.04) NA
16:g.50745945a G > A rs35285618 Non-syn 2123G > A R708H Crohn’s disease [6] A ¼ 0.005 1 (0.01) 0 (0) NA
16:g.50745996 C > G rs5743278 Non-syn 2174C > G 725G None G ¼ 0.018 1 (0.02) 1 (0.09) NA
16:g.50756540a G > C rs2066845 Non-syn 2722G > C G908R Crohn’s disease, [7,8]
Psoriatic arthritis [9]
C ¼ 0.004 1 (0.01) 0 (0) NA
16:g.50757276 G > A rs5743291 Non-syn 2863G > A V955I Crohn’s disease [15] A ¼ 0.03 6 (0.06) 4 (0.18) 0.50
Bold: Rare, non-synonymous variants that were only in cases.
SNP ¼ Single nucleotide polymorphism, 50 UTR ¼ 50 untranslated region, Syn ¼ Synonymous, Non-syn ¼ Non-synonymous, NA ¼ Not available.
a Rare, non-synonymous variants those were only present in cases.
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medication and a good visual acuity outcome.4. Discussion
We identiﬁed 18 polymorphisms in 51 patients with sarcoidosis,
which expands from prior work performed by Martin et al. [2] Our
study similarly found that NOD2 disease-associated genetic vari-
ants and common NOD2 variants are not associated with uveitis in
adult-onset sarcoidosis patients. Our sample size, albeit modest,
was larger than the previous study. Our study was also performed
at a time when the annotation of the human genome is more
complete, and we are better able to characterize the frequency and
potential pathogenicity of variants, particularly rare variants.
With this enhanced annotation of the human genome, we did
identify four rare polymorphisms that lead to protein changes and
were found only in patients with uveitis. The identiﬁcation of these
variants in only those with ocular manifestations is not sufﬁcient to
establish pathogenicity, particularly given their low MAF and the
limited number of controls without uveitis included in this study.
The potential pathogenicity needs to be further explored with
in vitro experiments. Given the signiﬁcant overlap in phenotype
between Blau syndrome and sarcoidosis and the important role of
NOD2 variation in a variety of inﬂammatory diseases, exploration of
NOD2 variants in a larger cohort could also help to assess whether
these or other rare variants may contribute to the development of
uveitis in a subset of sarcoidosis patients. Including sarcoidosis
uveitis patients without pulmonary involvement in such a cohort
may be particularly revealing as they may be closer phenotypically
to Blau syndrome patients in whom pulmonary involvement is not
common.5. Conclusions
Despite the phenotypic overlap between early onset sarcoidosis
and Blau syndrome, none of the Blau syndrome-associated NOD2
variants were present in adults with sarcoidosis. However, four
rare, non-synonymous variants were identiﬁed in four cases with
ocular sarcoidosis. Additional investigation with larger cohorts is
needed to explore the potential clinical signiﬁcance of these
variants.Financial support
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